Dexmedetomidine, an α2-adrenergic receptor agonist, also inhibits both NFAT5 and SIRT protein expression in a diabetic hyperglycemia-ischemia/reperfusion model, indirectly supporting NFAT5's role in diabetes-associated neurovascular damage 64. Here, NFAT5 is linked to ischemia.